Summary: Patency of the ductus arteriosus in preterm infants is mediated by vasodilating prostanoids; however, reliable methods to monitor prostanoid activity or production in preterm infants are lacking. We measured the excretion rates of major and characteristic urinary metabolites of prostacyclin (PGI2), PGE1 and PGE2, 6-keto-PGF1α, and 7α-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid (PGE-M), respectively. Besides these parameters which reflect total body prostanoid turnover and production, the urinary levels of PGE2 and PGF2α, the primary prostaglandins, were measured as an index of renal prostanoid synthesis. There were four study groups. One contained 11 thriving preterm infants; a second, six preterm infants with respiratory distress syndrome (RDS); a third, 30 preterm infants with RDS and patent ductus arteriosus (PDA); and a fourth, nine fullterm infants. All infants with RDS required artificial ventilation. There were no significant differences in PGE-M, PGE2 and PGF2α excretion rates among the various groups; however, a significant increase of the 6-keto-PGF1α excretion rates was observed in the groups of infants with RDS and with and without PDA (P < 0.01 and P < 0.02, respectively). Spontaneous (n = 2) or indomethacin-induced (n = 6) closure of PDA was associated with weaning from the respirator and a concomitant drop into the normal and subnormal range of the excretion rates of 6-keto-PGF1, (P < 0.01) and PGE-M (P < 0.02).
About this article
The Journal of Maternal-Fetal & Neonatal Medicine (2007)
Prostaglandins & Other Lipid Mediators (2007)
British Journal of Pharmacology (2003)
Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin
The Journal of Pediatrics (2003)
Prostaglandins & Other Lipid Mediators (2000)